Indisulam|CAS 165668-41-7|DC Chemicals

Cas No.:	165668-41-7
Chemical Name:	Indisulam
Synonyms:	Indisulam;N-(3-Chloro-1H-indol-7-yl)-1,4-benzenedisulfonamide;4-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide;1,4-Benzenedisulfonamide,N-(3-chloro-1H-indol-7-yl);E7070;Indisulam (IND);N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide;N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide;N1-(3-Chloro-1H-indol-7-yl)-1,4-benzenedisulfonamide;E-7070;ER-35744;IndisulaM (E7070);IndisulaM (E7070) (ER-35744);N1-(3-Chloro-1H-indol-7-yl)benzene-1,4-disulfonamide;1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)-;E 7070;WJ98J3NM90;N-(3-Chloro-1H-indol-7-yl)benzene-1,4disulfonamide;Indisulam (USAN/INN);N-(3-chl;INDISULAM;CS-0007710;FT-0740093;A904802;EF6;UNII-WJ98J3NM90;INDISULAM [WHO-DD];SB16544;indisulam (e7070);1-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide;indisulamum;INDISULAM [INN];Indisulam [USAN:INN:BAN];C14H12ClN3O4S2;HY-13650;1,4-BENZENEDISULFONAMIDE, N-(3-CHLORO-1H-INDOL-7-YL);165668-41-7;N(1)-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide;INDISULAM [USAN];C73201;Z2724205552;DB06370;1,4-Benzenedisulfonamide, N1-(3-chloro-1H-indol-7-yl)-;NS00068354;s9742;EN300-7378250;CHEMBL77517;N1-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide;GTPL7046;AKOS022181456;D04522;BCP06110;AS-69532;BDBM10890;CHEBI:145431;SCHEMBL91389;Q27078056;Indisulam, >=98% (HPLC);DTXSID50168008;n-(3-chloro-1h-indol-7-yl)-4-sulfamoylbenzenesulfonamide;INDISULAM [MI];AC-36646;N~1~-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide;N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide
SMILES:	ClC1=C([H])N([H])C2=C1C([H])=C([H])C([H])=C2N([H])S(C1C([H])=C([H])C(=C([H])C=1[H])S(N([H])[H])(=O)=O)(=O)=O
Formula:	C₁₄H₁₂ClN₃O₄S₂
M.Wt:	385.8458
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Indisulam (E7070) is potent, sulfonamide, cell-cycle inhibitor that possesses antiproliferative activities, causes decrease in the S phase fraction along with G1 and/or G2 accumulation in various cancer cell lines; causes blockade in the G1/S transition through inhibition of the activation of both cyclin-dependent kinase 2 and cyclin E, shows activity in multiple tumor types, most prominently in colon and lung cancer.Breast CancerPhase 2 Discontinued

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC67413	MRT-23227
DC67412	MRT-3486
DC67411	MRT-7612
DC67410	MRT-10350
DC67407	IKZF1-degrader-1	IKZF1-degrader-1 (Compound 9-B) is a highly potent molecular glue that achieves sub-nanomolar degradation of IKZF1 (DC50 = 0.134 nM), demonstrating significant therapeutic potential for targeting IKZF1-dependent malignancies.
DC67406	EM12-FS	EM12-FS is a bifunctional CRBN modulator that engages cereblon at His353 while functioning as a molecular glue to induce NTAQ1 degradation. Demonstrating favorable pharmacokinetics, it exhibits a human plasma half-life of 196 minutes, supporting its therapeutic potential.
DC67405	Acetyl-cyclosporin A aldehyde	Acetyl-cyclosporin A aldehyde is a chemically modified derivative of cyclosporin A (HY-B0579), featuring an acetyl group and a reactive aldehyde moiety. The parent compound, cyclosporin A, is a dual-function molecule that both inhibits calmodulin signaling and binds cyclophilin, thereby blocking NF-AT nuclear translocation and inducing mitochondrial dysfunction.
DC67404	QS-57	QS-57 is a bifunctional degrader that combines BRD4-targeting PROTAC activity with 14-3-3 molecular glue properties.
DC67403	KRAS ligand 4	KRAS ligand 4 (compound 2) is a SOS1-targeting bifunctional molecular glue that suppresses oncogenic signaling by degrading key KRAS pathway components, evidenced by reduced pERK and pS6 levels. It demonstrates broad-spectrum activity against diverse KRAS mutations, disrupting proliferation across resistant cancer models.
DC67402	Pomalidomide-15N,13C5	Pomalidomide-15N,13C5 is a stable isotope-labeled variant of pomalidomide (HY-10984), a third-generation immunomodulatory drug that functions as a cereblon-directed molecular glue. This compound mediates targeted ubiquitination and degradation of Ikaros family transcription factors (IKZF1/3) through recruitment of the CRL4CRBN E3 ligase complex, underpinning its therapeutic mechanism.